Lenmed Health Pty Ltd has acquired Mediclinic Kathu Pvt Hospital
Lenmed Health Pty Ltd has acquired the Mediclinic Kathu Pvt Hospital from Mediclinic Southern Africa for US$2 million.
Lenmed Health is an established black-owned hospital group in South Africa, operating multi-specialty hospital facilities in South Africa, Mozambique and Botswana and managing in excess of 1,300 beds.
The Mediclinic Kathu private hospital is situated in the iron ore capital of the Northern Cape between Upington and Vryburg.
Mediclinic Southern Africa is a private hospital group operating in South Africa and Namibia, focused on providing acute care, specialist-orientated, multi-disciplinary hospital services and related service offerings. The group currently operates 49 private hospitals in South Africa and 3 in Namibia, with more than 7,000 beds in total. Mediclinic Southern Africa is a wholly owned subsidiary of the South Africa-based international private healthcare group Mediclinic International, founded in 1983 and listed on the JSE since 1986.
Oaklins' team in South Africa advised the buyer in this transaction.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more